Objective:To evaluate the effects and adverse reactions of Boerning capsules plus FOLFOX4 regimen in clinical treatment for colon carcinoma.Methods:Total patients with colon carcinoma were randomly divided into two gr...Objective:To evaluate the effects and adverse reactions of Boerning capsules plus FOLFOX4 regimen in clinical treatment for colon carcinoma.Methods:Total patients with colon carcinoma were randomly divided into two groups from January 2005 to May 2006:group A(45 patients)were received Boerning capsules plus FOLFOX4 regimen treatment,and group B(49 patients)were received FOLFOX4 regimen treatment only.Results:Boerning capsules could obviously improve the life quality of the colon carcinoma patients.The weight gain in group A was higher than that of group B.No significant existed in the body immune function changes(T cell subgroup).But it could ameliorate the adverse reactions which induced by the chemotherapy.Conclusion:Boerning capsules can improve the life quality of the colon carcinoma patients and ame- liorate the symptoms and sign which induced by the chemotherapy.展开更多
Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (...Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin<sup><sup>®</sup></sup>) 85 mg/m<sup>2</sup> D1, 5-Fluorouracil 400 mg/m<sup>2</sup> IV push D1-2, 5-Fluorouracil 600 mg/m<sup>2</sup> IV drip in 22 hours D1-2 and Folinic acid 200 mg/m<sup>2</sup> IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible.展开更多
文摘Objective:To evaluate the effects and adverse reactions of Boerning capsules plus FOLFOX4 regimen in clinical treatment for colon carcinoma.Methods:Total patients with colon carcinoma were randomly divided into two groups from January 2005 to May 2006:group A(45 patients)were received Boerning capsules plus FOLFOX4 regimen treatment,and group B(49 patients)were received FOLFOX4 regimen treatment only.Results:Boerning capsules could obviously improve the life quality of the colon carcinoma patients.The weight gain in group A was higher than that of group B.No significant existed in the body immune function changes(T cell subgroup).But it could ameliorate the adverse reactions which induced by the chemotherapy.Conclusion:Boerning capsules can improve the life quality of the colon carcinoma patients and ame- liorate the symptoms and sign which induced by the chemotherapy.
文摘Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin<sup><sup>®</sup></sup>) 85 mg/m<sup>2</sup> D1, 5-Fluorouracil 400 mg/m<sup>2</sup> IV push D1-2, 5-Fluorouracil 600 mg/m<sup>2</sup> IV drip in 22 hours D1-2 and Folinic acid 200 mg/m<sup>2</sup> IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible.
